• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用可再利用药物和天然产物中的潜在先导化合物来应对非结核分枝杆菌。

Tackling Nontuberculous Mycobacteria by Repurposable Drugs and Potential Leads from Natural Products.

机构信息

Department of Natural Products, Chemical Sciences, National Institute of Pharmaceutical Education and Research-Hyderabad, Hyderabad, Balanagar, 500037, India.

出版信息

Curr Top Med Chem. 2024;24(15):1291-1326. doi: 10.2174/0115680266276938240108060247.

DOI:10.2174/0115680266276938240108060247
PMID:38288807
Abstract

Nontuberculous Mycobacteria (NTM) refer to bacteria other than all species that do not cause tuberculosis or leprosy, excluding the species of the complex, . NTM are ubiquitous and present in soils and natural waters. NTM can survive in a wide range of environmental conditions. The direct inoculum of the NTM from water or other materials is most likely a source of infections. NTMs are responsible for several illnesses, including pulmonary alveolar proteinosis, cystic fibrosis, bronchiectasis, chronic obstructive pneumoconiosis, and pulmonary disease. Recent reports suggest that NTM species have become insensitive to sterilizing agents, antiseptics, and disinfectants. The efficacy of existing anti-NTM regimens is diminishing and has been compromised due to drug resistance. New and recurring cases of multidrug-resistant NTM strains are increasing. Thus, there is an urgent need for ant-NTM regimens with novel modes of action. This review sheds light on the mode of antimicrobial resistance in the NTM species. Then, we discussed the repurposable drugs (antibiotics) that have shown new indications (activity against NTM strains) that could be developed for treating NTM infections. Also, we have summarised recently identified natural leads acting against NTM, which have the potential for treating NTM-associated infections.

摘要

非结核分枝杆菌(NTM)是指除引起结核和麻风病的所有种以外的细菌,不包括复合体的种。NTM 广泛存在于土壤和天然水中。NTM 可以在广泛的环境条件下生存。水或其他材料中 NTM 的直接接种物很可能是感染源。NTM 可引起多种疾病,包括肺泡蛋白沉积症、囊性纤维化、支气管扩张、慢性阻塞性肺疾病和肺部疾病。最近的报告表明,NTM 物种对杀菌剂、防腐剂和消毒剂的敏感性降低。由于耐药性,现有的抗 NTM 方案的疗效正在减弱。多药耐药性 NTM 菌株的新发病例和复发病例正在增加。因此,迫切需要具有新型作用模式的抗 NTM 方案。本综述阐明了 NTM 物种的抗菌耐药模式。然后,我们讨论了显示出新适应症(针对 NTM 菌株的活性)的可重新利用药物(抗生素),这些药物可用于治疗 NTM 感染。此外,我们还总结了最近发现的针对 NTM 的天然先导化合物,它们具有治疗与 NTM 相关感染的潜力。

相似文献

1
Tackling Nontuberculous Mycobacteria by Repurposable Drugs and Potential Leads from Natural Products.利用可再利用药物和天然产物中的潜在先导化合物来应对非结核分枝杆菌。
Curr Top Med Chem. 2024;24(15):1291-1326. doi: 10.2174/0115680266276938240108060247.
2
Activity of the Sudapyridine (WX-081) against Non-Tuberculous Mycobacteria Isolated in Beijing, China.苏达吡啶(WX-081)对中国北京分离的非结核分枝杆菌的活性。
Microbiol Spectr. 2022 Dec 21;10(6):e0137222. doi: 10.1128/spectrum.01372-22. Epub 2022 Oct 17.
3
Activities of Dual Combinations of Antibiotics Against Multidrug-Resistant Nontuberculous Mycobacteria Recovered from Patients with Cystic Fibrosis.从囊性纤维化患者中分离出的耐多药非结核分枝杆菌对抗生素双重组合的敏感性
Microb Drug Resist. 2018 Oct;24(8):1191-1197. doi: 10.1089/mdr.2017.0286. Epub 2018 Jan 25.
4
Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates.贝达喹啉和德拉马尼对非结核分枝杆菌(包括大环内酯类耐药临床分离株)的活性。
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00665-19. Print 2019 Aug.
5
Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria.非结核分枝杆菌的耐药机制与药敏试验。
Drug Resist Updat. 2012 Jun;15(3):149-61. doi: 10.1016/j.drup.2012.04.001. Epub 2012 Apr 21.
6
Identification of Non-Tuberculosis Mycobacteria by Line Probe Assay and Determination of Drug Resistance Patterns of Isolates in Iranian Patients.应用线性探针分析法鉴定非结核分枝杆菌并确定伊朗患者分离株的耐药模式
Arch Razi Inst. 2019 Dec;74(4):375-384. doi: 10.22092/ari.2019.127144.1372. Epub 2019 Dec 1.
7
Medications and monitoring in nontuberculous mycobacteria infections.非结核分枝杆菌感染的药物治疗与监测。
Clin Chest Med. 2015 Mar;36(1):55-66. doi: 10.1016/j.ccm.2014.11.001. Epub 2014 Dec 18.
8
activity of fidaxomicin against nontuberculosis mycobacteria.对非结核分枝杆菌的 fidaxomicin 活性。
J Med Microbiol. 2022 Jun;71(6). doi: 10.1099/jmm.0.001549.
9
Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches.非结核分枝杆菌性肺病中抗生素耐药的管理:挑战与新方法。
Expert Rev Respir Med. 2019 Sep;13(9):851-861. doi: 10.1080/17476348.2019.1638765. Epub 2019 Jul 8.
10
Sudapyridine (WX-081) antibacterial activity against , , and and .舒巴吡啶(WX-081)对 、 、 和 的抗菌活性。
mSphere. 2024 Feb 28;9(2):e0051823. doi: 10.1128/msphere.00518-23. Epub 2024 Jan 19.

引用本文的文献

1
Analysis of relative genes expression and mutation of pstB and efpA efflux pumps in Mycobacterium simiae isolates from suspected tuberculosis patients by using quantitative Real-time PCR.运用定量实时聚合酶链反应分析疑似结核病患者分离出的猿分枝杆菌中pstB和efpA外排泵的相关基因表达及突变情况。
BMC Microbiol. 2025 Mar 17;25(1):144. doi: 10.1186/s12866-025-03843-6.

本文引用的文献

1
Natural products acting against through membrane and cell wall disruption.通过破坏细胞膜和细胞壁发挥作用的天然产物。
Nat Prod Rep. 2023 Oct 18;40(10):1608-1646. doi: 10.1039/d2np00084a.
2
Flavonoids of (L.) R.M.King & H.Rob. as potential leads for treatment against tuberculosis.金氏金虎尾(学名:**(L.) R.M.King & H.Rob.** )的类黄酮作为抗结核治疗的潜在先导物 。 注:因不清楚括号内具体学名内容,保留了英文原样。如果括号内有具体学名,请根据实际情况翻译替换。
S Afr J Bot. 2023 Jul;158:158-165. doi: 10.1016/j.sajb.2023.05.002. Epub 2023 May 13.
3
Natural products and their analogues acting against Mycobacterium tuberculosis: A recent update.
天然产物及其类似物抗结核分枝杆菌的作用:最新进展。
Drug Dev Res. 2023 Aug;84(5):779-804. doi: 10.1002/ddr.22063. Epub 2023 Apr 21.
4
Repurposing β-Lactams for the Treatment of Infections: An In Vitro Study.β-内酰胺类药物用于治疗感染的新用途:一项体外研究
Antibiotics (Basel). 2023 Feb 5;12(2):335. doi: 10.3390/antibiotics12020335.
5
Targeting mycobacterial membranes and membrane proteins: Progress and limitations.靶向分枝杆菌膜及膜蛋白:进展与局限
Bioorg Med Chem. 2023 Mar 1;81:117212. doi: 10.1016/j.bmc.2023.117212. Epub 2023 Feb 11.
6
Tackling multidrug-resistant Staphylococcus aureus by natural products and their analogues acting as NorA efflux pump inhibitors.通过天然产物及其类似物作为NorA外排泵抑制剂来应对耐多药金黄色葡萄球菌。
Bioorg Med Chem. 2023 Feb 15;80:117187. doi: 10.1016/j.bmc.2023.117187. Epub 2023 Jan 27.
7
Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection.口腔替比培南-阿维巴坦在鼠分枝杆菌肺感染模型中的活性。
Antimicrob Agents Chemother. 2023 Feb 16;67(2):e0145922. doi: 10.1128/aac.01459-22. Epub 2023 Jan 23.
8
Clofazimine Inhalation Suspension Demonstrates Promising Toxicokinetics in Canines for Treating Pulmonary Nontuberculous Mycobacteria Infection.克拉法齐米尼吸入混悬剂在犬类肺部非结核分枝杆菌感染治疗中展现出有前景的毒代动力学特征。
Antimicrob Agents Chemother. 2023 Feb 16;67(2):e0114422. doi: 10.1128/aac.01144-22. Epub 2023 Jan 17.
9
Transcription Machinery: A Review on the Mycobacterial RNA Polymerase and Drug Discovery Efforts.转录机制:关于分枝杆菌RNA聚合酶及药物研发工作的综述
Life (Basel). 2022 Nov 3;12(11):1774. doi: 10.3390/life12111774.
10
Natural Products Lysobactin and Sorangicin A Show Activity against Mycobacterium abscessus Complex.天然产物 Lysobactin 和 Sorangicin A 对脓肿分枝杆菌复合物具有活性。
Microbiol Spectr. 2022 Dec 21;10(6):e0267222. doi: 10.1128/spectrum.02672-22. Epub 2022 Oct 31.